Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 1/20 | 0.44 |
| ▸ | CNR2 | P34972 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | KDM1A | O60341 | 3/20 | 0.38 |
| ▸ | RCOR1 | Q9UKL0 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | LPL | P06858 | 1/20 | 0.36 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.36 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12699223 | 0.88 | SKP2 (0.50) | CYP1A2CYP2D6CYP2C9CYP2C19NPSR1 | |
| SCHEMBL5866466 | 0.86 | HTR2A (0.48) | CA2TP53HSD17B10LPLLIPG | |
| SCHEMBL714794 | 0.85 | RARB (0.47) | CYP1A2CYP2D6CYP2C9CYP2C19NPSR1 | |
| SCHEMBL13564077 | 0.85 | HTR2A (0.52) | TP53HSD17B10LPLLIPG | |
| SCHEMBL7789300 | 0.85 | HTR2A (0.52) | TP53HSD17B10LPLLIPG | |
| SCHEMBL7788951 | 0.85 | HTR2A (0.52) | TP53HSD17B10LPLLIPG | |
| SCHEMBL2657319 | 0.83 | CYP1A2 (0.53) | CNR1CNR2CYP1A2CYP2D6CYP2C9 | |
| SCHEMBL30655473 | 0.83 | TRPA1 (0.41) | CYP1A2CYP2D6CYP2C9CYP2C19NPSR1 | |
| SCHEMBL8436651 | 0.83 | TRPA1 (0.41) | CYP1A2CYP2D6CYP2C9CYP2C19NPSR1 | |
| SCHEMBL1128476 | 0.81 | TAAR1 (0.52) | CYP1A2CYP2D6CYP2C19TP53HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240025902-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADATION OF EGFR AND RELATED METHODS OF USE | BEONE MEDICINES I GMBH (CH) | 2024-01-25 | — | — | US | disclosed |
| EP-3746444-B1 | CYCLOALKYL SUBSTITUTED PYRAZOLOPYRIMIDINES HAVING ACTIVITY AGAINST RSV | JANSSEN SCIENCES IRELAND UNLIMITED CO (IE) | 2023-09-27 | — | — | EP | disclosed |
| US-20230265116-A1 | DEGRADATION OF (EGFR) BY CONJUGATION OF EGFR INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | BEONE MEDICINES I GMBH (CH) | 2023-08-24 | — | — | US | disclosed |
| CN-107794057-B | Negative liquid crystal compound, liquid crystal mixture and application thereof | 晶美晟光电材料（南京）有限公司 | 2021-03-23 | — | — | CN | disclosed |
| EP-3455328-B1 | BIMESOGENIC COMPOUNDS AND MESOGENIC MEDIA | MERCK PATENT GMBH (DE) | 2020-03-04 | — | — | EP | disclosed |
| WO-2019149734-A1 | CYCLOALKYL SUBSTITUTED PYRAZOLOPYRIMIDINES HAVING ACTIVITY AGAINST RSV | Janssen Sciences Ireland Unlimited Company (IE) | 2019-08-08 | — | — | WO | disclosed |
| WO-2017194665-A1 | BIMESOGENIC COMPOUNDS AND MESOGENIC MEDIA | MERCK PATENT GMBH (DE) | 2017-11-16 | — | — | WO | disclosed |
| EP-1900792-B1 | Fluorine phenyl compounds for liquid crystalline mixtures | MERCK PATENT GMBH (DE) | 2010-08-04 | — | — | EP | disclosed |
| US-7767277-B2 | Fluorophenyl compounds for liquid-crystalline mixtures | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2010-08-03 | — | — | US | disclosed |
| US-7767277-B2 | Fluorophenyl compounds for liquid-crystalline mixtures | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2010-08-03 | — | — | US | disclosed |
| US-20080132716-A1 | difluoromethyleneoxy group bridge on fluorinated biphenyl and fluorinated phenyl group; electro-optical displays; high dielectric anisotropy, high clearing point and low rotational viscosity; photochemically stable, heat resistance; chemical intermediates | MERCK PATENT GMBH | 2008-06-05 | — | — | US | disclosed |
| EP-1900792-A1 | Fluorine phenyl compounds for liquid crystalline mixtures | Merck Patent GmbH (DE) | 2008-03-19 | — | — | EP | disclosed |
| US-7300936-B2 | α-(N-sulfonamido)acetamide derivatives as β-amyloid inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-11-27 | — | — | US | disclosed |
| CN-1911880-A | Multifluoro substituted diphenyl acetylene derivative, composition containing multifluoro substituted diphenyl acetylene derivatire, its preparation method and use | SHIJIAZHUANG YONGSHENGHUAQING (CN) | 2007-02-14 | — | — | CN | disclosed |
| EP-0648723-B1 | Diphenylacetylene compound, process for preparing the same and liquid crystal composition and element comprising the same | SUMITOMO CHEMICAL CO (JP) | 1998-05-20 | — | — | EP | disclosed |
| US-5658489-A | EXCELLENT ANISOTROPY OF REFRACTIVE INDEX; LOW VISCOSITY | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1997-08-19 | — | — | US | disclosed |
| EP-0413785-B1 | LIQUID CRYSTALLINE MEDIA CONTAINING FLUORINATED OLIGOPHENYLS | MERCK PATENT GMBH (DE) | 1995-12-20 | — | — | EP | disclosed |
| EP-0648723-A1 | Diphenylacetylene compound, process for preparing the same and liquid crystal composition and element comprising the same | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 1995-04-19 | — | — | EP | disclosed |
| EP-0413785-A1 | LIQUID CRYSTALLINE MEDIA CONTAINING FLUORINATED OLIGOPHENYLS. | MERCK PATENT GMBH (DE) | 1991-02-27 | — | — | EP | disclosed |
| WO-1990009420-A1 | LIQUID CRYSTALLINE MEDIA CONTAINING FLUORINATED OLIGOPHENYLS | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 1990-08-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230265116-A1 | DEGRADATION OF (EGFR) BY CONJUGATION OF EGFR INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | EGFR, CBL, ERBB2 | CNR1 4092/4885CNR2 4396/4885CYP1A2 4616/4885 |
| US-20240025902-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADATION OF EGFR AND RELATED METHODS OF USE | EGFR, ERBB2, CBL | CNR1 4236/4885CNR2 4376/4885CYP1A2 4612/4885 |
| US-20080132716-A1 | difluoromethyleneoxy group bridge on fluorinated biphenyl and fluorinated phenyl group; electro-optical displays; high dielectric anisotropy, high clearing point and low rotational viscosity; photochemically stable, heat resistance; chemical intermediates | FLNB, FLNA, BRAF | CNR1 2003/4885CNR2 2677/4885CYP1A2 635/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.